Workflow
ADR
icon
Search documents
X @The Economist
The Economist· 2025-07-06 11:30
Jiangsu’s party cadres find success with a bizarre idea https://t.co/olcy02c8KU ...
Caesars Entertainment(CZR) - 2018 Q4 - Earnings Call Presentation
2025-07-03 07:53
4Q and FY 2018 Earnings • February 21, 2019 CAESARS ENTERTAINMENT CORPORATION 1 Forward Looking Statements Certain information in this presentation and discussed on the conference call which this presentation accompanies constitutes forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical or current facts and by the use of words such as "will," "may," "expect," "project ...
I miei dieci condomini colorati | ELENA SALZANO | TEDxAngri
TEDx Talks· 2025-07-01 15:33
[Musica] [Musica] [Applauso] In tanti ogni giorno vivono almeno 10 vite, 10 condomini. utilizzano 10 linguaggi, 10 personalità con esigenze specifiche e anche con un una bacheca comune. C'è chi si chiede come si fa, ma io non ho la risposta perfetta, però penso possiamo partire da tre cose fondamentali: un'agenda, uno sguardo oltre l'orizzonte e una voglia infinita di esserci.esserci perché in un mondo a colori dove ogni impegno ha un cuore, ogni progetto ha una voce e ogni ora ha un'identità, significa pot ...
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
Prnewswire· 2025-06-30 20:05
SAN DIEGO, June 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of investigational compound NBIP-01435 in healthy adult participants. NBIP-01435 is a long-acting corticotropin-releasing factor type 1 receptor antagonist administered as a subcutaneous injection for the potential treatment of congenital adrenal hyperplasia (C ...
Boqii Announces Plan to End ADR Program and Consolidate Ordinary Shares to Trade on AMEX
Prnewswire· 2025-06-27 21:00
SHANGHAI, June 27, 2025 /PRNewswire/ -- Boqii Holding Limited ("Boqii" or the "Company") (NYSE American: BQ) today announced that it will terminate the Deposit Agreement dated September 29, 2020 (the "Termination"), among the Company, The Bank of New York Mellon (the "Depositary"), and the owners and holders of American depositary shares (the "ADSs") from time to time in the near future, which was approved by its shareholders on June 26, 2025. In conjunction with this Termination, the Company will effect a ...
台积电:考虑过普通股转换ADR 目前不打算
news flash· 2025-06-03 03:35
台积电:考虑过普通股转换ADR 目前不打算 智通财经6月3日电,台积电召开股东常会,期间有股东提问台积电台股现股表现落后ADR报酬,台积 电财务长黄仁昭表示,公司考虑过普通股转换ADR,不过怕冲击ADR价格与台股现股,目前不打算。 黄仁昭说,后续若市场稳定一点再来可以开放,公司研究持续观察市场情况也请投资银行研究。 ...
湾区法律专家共议仲裁制度创新 为中国企业“走出去”保驾护航
在全球经济深度调整与国内产业转型升级的双重驱动下,中国企业正加速"走出去"。然而日益复杂的国际贸易环境为企业"走出去"增加了诸多不确定性—— 技术封锁、关税壁垒、非关税贸易限制措施不断升级;各国法律体系差异显著,数据安全、知识产权、反垄断等领域的合规要求愈发严苛。 在此背景下,仲裁作为国际通行的商事纠纷解决方式,因其具有尊重当事人意思自治、高效便捷、保密性强、一裁终局、域外可执行等独特优势,成为保障 企业海外发展的关键力量。 2025年5月15日下午,第二届粤港澳大湾区多元纠纷解决交流会(以下简称"交流会")在广州黄埔成功举办。本次交流会由中国海事仲裁委员会大湾区仲裁 中心(华南分会)主办,中国海事仲裁委员会、广州开发区管理委员会、广州市黄埔区人民政府、广州市港务局共同支持。 《中国经营报》记者了解到,交流会以"粤港澳大湾区多元纠纷解决"为主题,邀请了近20位粤港澳大湾区仲裁法律界、企业实务界、学术界专家围绕"仲裁 制度规则创新""航运保险热点法律问题""中国企业'走出去'法律风险防范与纠纷解决"三个议题展开专业交流和研讨。 会议期间,广东省贸促会副会长崔爽指出,广东省贸促会近年来在加强涉外商事法律服务、建立 ...
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
Prnewswire· 2025-05-16 12:30
One-Year Data Show Lasting Reductions in Glucocorticoid Doses and Improvements in Clinical Outcomes with CRENESSITY™ (crinecerfont) in Pediatric Patients with Classic Congenital Adrenal Hyperplasia SAN DIEGO, May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present new data from the Phase 3 CAHtalyst™ Pediatric study showing lasting reductions in glucocorticoid doses in pediatric patients with classic congenital adrenal hyperplasia who received CRENESSITY™ (cr ...
Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)
Prnewswire· 2025-05-15 20:05
90% of Pediatric Participants on CRENESSITY versus 21% on Placebo Achieved ≥1 Threshold for Androstenedione Reduction or Glucocorticoid Reduction Observed Rates of Select Reproductive Hormone Normalization in Adult Males Taking CRENESSITY with Substantial Glucocorticoid Dose Reductions Findings Presented at the 2025 American Association of Clinical Endocrinology Annual MeetingSAN DIEGO, May 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 3 CAHtal ...
Sotherly Hotels(SOHO) - 2025 Q1 - Earnings Call Transcript
2025-05-13 15:00
Sotherly Hotels (SOHO) Q1 2025 Earnings Call May 13, 2025 10:00 AM ET Speaker0 Good morning, all, and thank you for joining us for the Suverley Hotels Q1 twenty twenty five Conference Call and Webcast. My name is Carly, and I'll be coordinating the call today. I'd now like to hand over to our host, Scott Kukinski, Chief Operating Officer of Suvley Hotels. The floor is yours. Speaker1 Thank you, and good morning, everyone. If you've not received a copy of the earnings release, you may access it on our websit ...